Present IconHave an Alzheimer's or MCI diagnosis?
Receive a free test by participating in our study →
NeuroAge Therapeutics logo
AD-Detect blood test illustration
Quest Diagnostics workflowAβ42/40 + p-tau217Alzheimer's-focused

AD-Detect Blood Test

AD-Detect is NeuroAge's Alzheimer's-focused blood test, using the Quest Diagnostics workflow to measure Aβ42/40 and p-tau217 and support personalized recommendations based on Alzheimer's-related biomarkers.

$799

This page is specifically about Alzheimer's-related pathology biomarkers rather than a broader RNA-style biomarker panel, with personalized recommendations guided by those findings.

  • Plasma amyloid ratios (AB42/40)
  • Phosphorylated tau levels (p-tau181 and p-tau217)
  • Personalized recommendations for a more youthful brain
Purchase AD-Detect
The Wall Street Journal
Nature Aging
New Scientist
Forbes
eLife
WHY IT MATTERS

When your main question is Alzheimer's pathology, specificity matters

AD-Detect is designed for people who want an Alzheimer's-focused biomarker signal rather than a broader biological aging panel.

NeuroAge's current science materials describe AD-Detect through a Quest Diagnostics blood-draw workflow. The product focuses on blood-based Alzheimer's biomarkers, including Aβ42/40 and p-tau217.

That makes AD-Detect distinct from the broader Blood Biomarkers Test. This page is intentionally centered on Alzheimer's-related pathology rather than upstream biology in general, so recommendations can be interpreted in a more targeted context.

Specificity

Focus on Alzheimer's-related markers rather than a broad molecular panel.

Convenience

Use the Quest Diagnostics workflow for a standard blood draw experience.

Context

Add AD-Detect to genetics, MRI, NeuroGames, or coaching when you want a fuller prevention picture.

BEST FOR

Best for people whose main question is Alzheimer's-specific risk or pathology

AD-Detect is a strong fit when you want a more targeted blood test rather than a broader biomarker panel.

People focused on Alzheimer's

Choose this product when your main concern is Alzheimer's-related pathology rather than general biological aging.

People who want a non-imaging option

Use a blood draw when you want a targeted signal without starting with MRI.

People layering modalities

Combine AD-Detect with genetics, cognition, or imaging for broader context if desired.

OUR SCIENCE

Quest Diagnostics workflow with Aβ42/40 and p-tau217

This page is intentionally distinct from the broader Blood Biomarkers Test.

NeuroAge's current science materials describe AD-Detect as a Quest Diagnostics blood-draw workflow centered on Alzheimer's biomarkers. The highlighted markers include Aβ42/40 and p-tau217, which are framed as the product's core pathology-focused signals.

That narrower focus is the point. AD-Detect is for people who want an Alzheimer's-specific blood-based layer, while the broader Blood Biomarkers Test is designed around upstream biology such as neuroinflammation, mitochondrial function, and cellular stress.

AD-Detect focus

  • Quest Diagnostics workflow for a standard blood draw.
  • Aβ42/40 and p-tau217 as the emphasized biomarkers.
  • An Alzheimer's-specific positioning distinct from the broader biomarker page.
RESULTS DASHBOARD

Keep Alzheimer's-focused results visible

The dashboard section helps place AD-Detect results alongside your broader NeuroAge context when needed.

Review Alzheimer's-focused blood findings in a clearer visual format.

Keep pathology-oriented results accessible for follow-up conversations and personalized recommendations.

Pair AD-Detect with other product results when you want broader context.

NeuroAge dashboard illustrating Alzheimer's-focused blood biomarker review

Client Testimonials

What NeuroAge customers are saying across imaging, testing, and coaching.

I live my life profoundly between my ears - I enjoy learning and thinking and reading and writing and making things. The prospect of losing those abilities, and losing the memories that they have created, frightens me.If you have a family history like mine, this assessment can help you better understand your risk of Alzheimer's and how you're doing so far. It can give you the incentive you need to manage your risk more thoughtfully.
Mike OlsonMike Olson
NeuroAge Therapeutics is an amazing and best in class company led by the very best Co-founder and CEO.I have been impressed since day one. They produce positive results and guidance. I unequivocally recommend NeuroAge Therapeutics.
Carol DiBattisteCarol DiBattiste
I've worked with NeuroAge for several years across their full platform - including MRI analysis, genetics, blood biomarkers, cognitive tests and personalised coaching on the key pillars of healthy brain aging.What sets them apart is the integration: a holistic view of where my brain health stands today, drawing together all the available data and tracked over time, combined with a practical framework for what to do about it. The focus is squarely on prevention and the insights are specific, actionable and evidence based.For anyone serious about the cutting edge of preventive brain health, I can't recommend NeuroAge highly enough.
Jamie GarisJamie Garis
The most comprehensive brain health assessment I've ever done — and it may have saved my life.NeuroAge caught a brain aneurysm that Prenuvo missed entirely on THREE scans. That alone made the whole experience worth it. But what really sets NeuroAge apart is the depth of what they actually measure — this isn't just a scan.My assessment combined a brain MRI analyzed across 25 regions, cognitive testing through their NeuroGames platform, blood biomarkers, and whole genome sequencing. Everything feeds into a single NeuroAge score. Mine came back 6 years younger than my chronological age, which puts me in the 80th percentile — but more importantly, I now know exactly which areas to work on (thalamus, white matter, hippocampus) and have a personalized, evidence-based plan to address them.The genetic component is where it gets really interesting — I learned about medically actionable variants that affect how I metabolize certain medications, including a VKORC1 variant relevant to blood thinners and a CYP2C19 variant affecting a range of common drugs. That's information I'll carry to every doctor's appointment.The reporting is thorough, the recommendations are backed by citations, and the level of personalization is unlike anything I've experienced in conventional medicine. If you're serious about proactive brain health, this is where to start.
Laurie ZugayLaurie Zugay
In January I attended the R42 Healthcare Retreat at the Ritz Carlton in Half Moon Bay. Multiple tests were included in the price. The brilliant, Alzheimer trailblazer,Christin Glorioso, M.D. was in charge of coordinating the brain MRI's and other cognitive tests for the retreat through her company, NeuroAge Therapeutics. She founded, to prevent and treat Alzheimer's which had decimated her family. She flagged my brain MRI as abnormal and possible NPH. NPH is a rare condition that affects balance, cognitive decline and urinary incontinance aka “wet, wobbly and wacky.” She contacted me and strongly suggested that I consult with a neurologist and assured me that it was treatable which was a massive relief. But for Dr. Glorioso this rare, treatable condition would have never been found.Thank you Christin for alerting me and staying with me while I went through the testing (including a spinal tap to relieve the spinal tap to release the pressure in my brain) to confirm the diagnosis. This is a rare condition and never would have been discovered but for the brain MRI and the determination of Dr. Glorioso.
Marisa McGinnisMarisa McGinnis
FAQ

Questions, answered

NeuroAge's current science materials emphasize Aβ42/40 and p-tau217 as the core Alzheimer's-focused biomarkers for AD-Detect.

After purchase, you visit a Quest Diagnostics location for a standard blood draw. The product is built around that Quest Diagnostics workflow.

AD-Detect is centered on Alzheimer's-related pathology markers. The Blood Biomarkers Test is positioned around broader brain-aging biology instead.

No. It is an Alzheimer's-focused biomarker product that can inform next-step discussions, but it does not replace physician-led diagnosis.

Add an Alzheimer's-focused blood biomarker layer

Use the Quest Diagnostics workflow to access Aβ42/40 and p-tau217 in a more targeted product with personalized recommendations for next steps.